Image

Europe Adalimumab Market – Industry Trends and Forecast to 2029

Pharmaceutical

Image

Europe Adalimumab Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Published Report
  • May 2022
  • Europe
  • 350 Pages
  • No of Tables: 218
  • No of Figures: 54

Europe Adalimumab Market, By Indication (Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn's Disease, Hidradenitis Suppurativa, Ulcerative Colitis, Chronic Plaque Psoriasis, Non-Infectious Intermediate and Others), Type (Biologics and Biosimilars), Dosage Strength (20MG/0.4MLG, 40MG/0.8MLG and Others), Drug Type (Humira, Amgevita, Imraldi, Hyrimoz, Yuflyma, Hulio, Idacio), Population Type (Children and Adults), End User (Hospitals, Specialty Clinics, Home Healthcare and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others) Industry Trends and Forecast to 2029.

Europe Adalimumab Market

Market Definition

Adalimumab is one of the monoclonal antibodies used to treat certain autoimmune diseases involving rheumatoid arthritis, Crohn’s diseases, among others. Adalimumab is an anti-TNF drug indicated for the treatment of inflammatory symptoms. The biologic of adalimumab is Humira and various biosimilar drugs of Humira are also available, which involves Exemptia, Hyrimoz, Cyltezo, and Hulio among others. Adalimumab works by binding to the TNF factor alpha, which reduces the chances of the inflammatory response to autoimmune diseases.

Market Analysis and Insights

Europe adalimumab market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 16.2% in the forecast period of 2022 to 2029 and is expected to reach USD 10,337.79 million by 2029 from USD 3,485.94 million in 2021.

Europe Adalimumab Market

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020

Quantitative Units

Revenue in USD Million

Segments Covered

By Indication (Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn's Disease, Hidradenitis Suppurativa, Ulcerative Colitis, Chronic Plaque Psoriasis, Non-Infectious Intermediate and Others), Type (Biologics and Biosimilars), Dosage Strength (20MG/0.4MLG, 40MG/0.8MLG and Others), Drug Type (Humira, Amgevita, Imraldi, Hyrimoz, Yuflyma, Hulio, Idacio), Population Type (Children and Adults), End User (Hospitals, Specialty Clinics, Home Healthcare and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others)

Countries Covered

Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Belgium, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland and Rest of Europe

Market Players Covered

The major companies which are dealing in the market are AbbVie Inc. Sandoz International GmbH, Amgen Inc., Mylan N.V. (A subsidiary of Viatris), Biogen, Celltrion Healthcare Co., Ltd., Fresenius Kabi SwissBioSim GmbH, Alvotech, Biocad, Coherus BioSciences, Shanghai Henlius Biotech, Inc., Synermore Biologics, Prestige BioPharma Ltd., and Janssen Global Services, LLC among others

Adalimumab Market Dynamics

Drivers

  • Increasing prevalence of rheumatoid arthritis

The prevalence of rheumatoid arthritis is increasing worldwide and this has been reported that globally, the annual incidence of RA is nearly 3 cases per 10,000 populations. Rheumatoid arthritis leads to development of inflammatory symptoms which can be treated by several drug therapies involving biological therapies among others. One of the most innovative biological therapy discovered for treatment of rheumatoid arthritis includes adalimumab, a monoclonal antibody which targets the immune cells and slows down the recruitment of immune cells that leads to decrease the inflammation at target site. The continuous rise in rheumatoid arthritis globally and in the European region has badly affected the life of sufferers and thus disease is also putting a great burden over the healthcare professionals.

  • Rise in geriatric population

The geriatric population is increasing living for longer period of time with several types of chronic conditions. This has been reported that the pace of ageing population is too high and is expanding at a dramatic rate. The condition of rheumatoid arthritis is said to be associated with increase in older population. According to a study, about 703 million people were over the age of 65 years old or over in the year 2019. North America and Europe had over 200 million older age people. The study also suggested that the population has already been observed to be significantly older and rising slowly about 48%. Adult’s population suffering from rheumatoid arthritis is increasing who are largely dependent on adalimumab therapy. This thus signifies that increasing geriatric population is acting as driver for market growth.

  • Increasing number of contract research organizations (CRO)

Contract research organizations provide with the support for clinical trials and other research activities conducted for drugs and medical devices. Contract Research Organisation (CRO) helps biotechnology and pharmaceutical industries for the drug development process and to reduce the overall cost of clinical trials. As various adalimumab are extensively under the clinical trials in order to fulfil the unmet demands of patients suffering from inflammatory diseases, the increasing number of contract research organizations is boosting the market growth. There is an increase in the number of contract research organizations which has simplified the process of adalimumab drugs and reduced the time needed for drug development.

Europe Adalimumab Market

Opportunities

  • Strategic initiatives by market players

The demand for adalimumab has boosted in the region as well as globally, due to the growth in the rise in various chronic diseases and the rise in geriatric population. These favourable factors accomplishing enhance the need for the drugs, and to accomplish the market demand, minor and major market players are utilizing various strategies

Also, the rise in healthcare expenditure by the government in the region will provide structural integrity and future opportunities for the adalimumab market in the forecast period of 2022-2029.

Restraints/Challenges

However, the high cost associated with the drugs and some side effects seen after using drugs may hamper the growth of the market. Additionally, stringent rules and regulations will further challenge the market in the forecast period mentioned above.

This adalimumab market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on arthritis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Post COVID-19 Impact on Adalimumab Market

The COVID-19 has not that much affected in the growth of the market. As there is rise in the prevalence of various diseases in the region such as rheumatoid arthritis, Crohn’s diseases and among others lead to rise in the development of various drugs in the market. Hence the need for the adalimumab drugs keep rising in the COVID-19 period as well.

Recent Development

  • In October 2018, Sandoz, a Novartis division and the pioneer and global leader in biosimilars, today announced that the US Food and Drug Administration (FDA) approved its biosimilar, HyrimozTM (adalimumab-adaz). The FDA granted approval for the treatment of rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA) in patients four years of age and older, psoriatic arthritis (PsA), ankylosing spondylitis (AS), adult Crohn's disease (CD), ulcerative colitis (UC) and plaque psoriasis (Ps).

Europe Adalimumab Market Scope

Europe adalimumab market is segmented into indication, type, dosage strength, drug type, population type, end user and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Indication

  • Rheumatoid Arthritis
  • Juvenile Idiopathic Arthritis
  • Psoriatic Arthritis
  • Ankylosing Spondylitis
  • Crohn’s Disease
  • Hidradenitis Suppurativa
  • Ulcerative Colitis
  • Chronic Plaque Psoriasis
  • Non-Infectious Intermediate
  • Others

On the basis of indication, Europe adalimumab market is segmented into rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, hidradenitis suppurativa, ulcerative colitis, chronic plaque psoriasis, non-infectious intermediate and others.

Type

On the basis of type, Europe adalimumab market is segmented into biologics and biosimilars.

Dosage Strength

  • 20MG/0.4MLG
  • 40MG/0.8MLG
  • Others

On the basis of dosage strength, Europe adalimumab market is segmented into 20MG/0.4MLG, 40MG/0.8MLG and others.

Drug Type

  • Humira
  • Amgevita
  • Imraldi
  •  Hyrimoz
  •  Yuflyma
  •  Hulio
  •  Idacio

On the basis of drug type, Europe adalimumab market is segmented into Humira, Amgevita, Imraldi, Hyrimoz, Yuflyma, Hulio and Idacio.

Population Type

  • Children
  • Adults

On the basis of population type, Europe adalimumab market is segmented into children and adults.

End User

  • Hospitals
  • Specialty Clinics
  • Home Healthcare
  • Others

On the basis of end-users, Europe adalimumab market is segmented into hospital, specialty clinics, home healthcare and others.

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Europe Adalimumab Market

On the basis of distribution channel, Europe adalimumab market is segmented into hospital pharmacies, retail pharmacies, online pharmacies and others.

Adalimumab Market Regional Analysis/Insights                   

The adalimumab market is analysed and market size insights and trends are provided by country, indication, type, dosage strength, drug type, population type, end user and distribution channel as referenced above.

Europe adalimumab market is further segmented into following countries - Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Belgium, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland and Rest of Europe.

Germany dominates the adalimumab market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to rise in prevalence of various chronic diseases and research and development in the drug development in the Germany region further improves this market growth.

The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of global brands and their challenges faced due to high competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Market Share Analysis

The adalimumab market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on adalimumab market.

Some of the major players operating in the adalimumab market are AbbVie Inc. Sandoz International GmbH, Amgen Inc., Mylan N.V. (A subsidiary of Viatris), Biogen, Celltrion Healthcare Co., Ltd., Fresenius Kabi SwissBioSim GmbH, Alvotech, Biocad, Coherus BioSciences, Shanghai Henlius Biotech, Inc., Synermore Biologics, Prestige BioPharma Ltd., Janssen Global Services, LLC among others.

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analysed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Europe vs. Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report


SKU-

LIST OF TABLES

TABLE 1 EUROPE ADALIMUMAB MARKET, PIPELINE ANALYSIS

TABLE 2 BIOSIMILAR OF ADALIMUMAB LAUNCHED IN THE U.S.

TABLE 3 PREVALENCE AND INCIDENCE RATES OF RA WORLDWIDE (CASE PER 100 INHABITANTS)

TABLE 4 BIOLOGIC DRUGS SUBJECTED TO PATENT LOSS

TABLE 5 ALTERNATIVE DRUGS FOR INFLAMMATORY DISEASES TREATMENT

TABLE 6 EUROPE ADALIMUMAB MARKET, BY INDICATION 2019-2027 (USD MILLION)

TABLE 7 EUROPE RHEUMATOID ARTHRITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 8 EUROPE ANKYLOSING SPONDYLITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 9 EUROPE CHRONIC PLAQUE PSORIASIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 10 EUROPE CROHN’S DISEASE IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 11 EUROPE ULCERATIVE COLITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 12 EUROPE PSORIATIC ARTHRITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 13 EUROPE JUVENILE IDIOPATHIC ARTHRITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 14 EUROPE HIDRADENITIS SUPPURATIVA IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 15 EUROPE NONINFECTIOUS INTERMEDIATE IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 16 EUROPE OTHERS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 17 EUROPE ADALIMUMAB MARKET, BY TYPE 2019-2027 (USD MILLION)

TABLE 18 EUROPE BIOLOGICS IN ADALIMUMAB MARKET, BY TYPE 2019-2027 (USD MILLION)

TABLE 19 EUROPE BIOSIMILARS IN ADALIMUMAB MARKET, BY TYPE 2019-2027 (USD MILLION)

TABLE 20 EUROPE BIOSIMILARS IN ADALIMUMAB MARKET, BY TYPE 2019-2027 (USD MILLION)

TABLE 21 EUROPE ADALIMUMAB MARKET, BY DOSAGE STRENGHT, 2019-2027 (USD MILLION)

TABLE 22 EUROPE 40MG/0.4ML IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 23 EUROPE 80MG/0.8ML IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 24 EUROPE 20MG/0.4ML IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 25 EUROPE 10MG/0.1ML IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 26 EUROPE OTHERS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 27 EUROPE ADALIMUMAB MARKET, BY DRUG TYPE, 2019-2027 (USD MILLION)

TABLE 28 EUROPE BRANDED IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 29 EUROPE GENERICS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 30 EUROPE GENERICS ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 31 EUROPE ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION 2019-2027 (USD MILLION)

TABLE 32 EUROPE PARENTERAL IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 33 EUROPE ADALIMUMAB MARKET, BY POPULATION TYPE, 2019-2027 (USD MILLION)

TABLE 34 EUROPE ADULTS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 35 EUROPE CHILDREN IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 36 EUROPE ADALIMUMAB MARKET, BY END USER, 2019-2027 (USD MILLION)

TABLE 37 EUROPE HOSPITALS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 38 EUROPE SPECIALTY CLINICS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 39 EUROPE HOME HEALTHCARE IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 40 EUROPE OTHERS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 41 EUROPE ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)

TABLE 42 EUROPE HOSPITAL PHARMACIES IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 43 EUROPE RETAIL PHARMACIES IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 44 EUROPE ONLINE PHARMACIES IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 45 EUROPE DIRECT TENDER IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 46 EUROPE OTHERS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 47 EUROPE ADALIMUMAB MARKET, BY COUNTRY, 2018-2027 (USD MILLION)

TABLE 48 EUROPE ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 49 EUROPE ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 50 EUROPE BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 51 EUROPE ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 52 EUROPE ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 53 EUROPE GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 54 EUROPE ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 55 EUROPE ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 56 EUROPE ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 57 EUROPE ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 58 GERMANYADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 59 GERMANYADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 60 GERMANYBIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 61 GERMANYADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 62 GERMANYADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 63 GERMANY GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 64 GERMANYADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 65 GERMANYADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 66 GERMANYADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 67 GERMANYADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 68 U.K ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 69 U.K ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 70 U.K BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 71 U.K ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 72 U.K ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 73 U.K GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 74 U.K ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 75 U.K ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 76 U.K ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 77 U.K ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 78 ITALY ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 79 ITALY ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 80 ITALY BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 81 ITALY ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 82 ITALY ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 83 ITALY GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 84 ITALY ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 85 ITALY ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 86 ITALY ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 87 ITALY ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 88 FRANCE ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 89 FRANCE ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 90 FRANCE BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 91 FRANCE ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 92 FRANCE ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 93 FRANCE GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 94 FRANCE ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 95 FRANCE ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 96 FRANCE ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 97 FRANCE ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 98 SPAIN ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 99 SPAIN ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 100 SPAIN BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 101 SPAIN ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 102 SPAIN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 103 SPAIN GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 104 SPAIN ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 105 SPAIN ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 106 SPAIN ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 107 SPAIN ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 108 NETHERLANDS ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 109 NETHERLANDS ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 110 NETHERLANDS BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 111 NETHERLANDS ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 112 NETHERLANDS ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 113 NETHERLANDS GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 114 NETHERLANDS ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 115 NETHERLANDS ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 116 NETHERLANDS ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 117 NETHERLANDS ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 118 RUSSIA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 119 RUSSIA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 120 RUSSIA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 121 RUSSIA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 122 RUSSIA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 123 RUSSIA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 124 RUSSIA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 125 RUSSIA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 126 RUSSIA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 127 RUSSIA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 128 SWITZERLAND ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 129 SWITZERLAND ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 130 SWITZERLAND BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 131 SWITZERLAND ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 132 SWITZERLAND ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 133 SWITZERLAND GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 134 SWITZERLAND ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 135 SWITZERLAND ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 136 SWITZERLAND ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 137 SWITZERLAND ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 138 BELGIUM ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 139 BELGIUM ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 140 BELGIUM BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 141 BELGIUM ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 142 BELGIUM ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 143 BELGIUM GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 144 BELGIUM ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 145 BELGIUM ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 146 BELGIUM ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 147 BELGIUM ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 148 TURKEY ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 149 TURKEY ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 150 TURKEY BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 151 TURKEY ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 152 TURKEY ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 153 TURKEY GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 154 TURKEY ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 155 TURKEY ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 156 TURKEY ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 157 TURKEY ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 158 AUSTRIA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 159 AUSTRIA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 160 AUSTRIA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 161 AUSTRIA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 162 AUSTRIA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 163 AUSTRIA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 164 AUSTRIA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 165 AUSTRIA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 166 AUSTRIA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 167 AUSTRIA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 168 NORWAY ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 169 NORWAY ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 170 NORWAY BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 171 NORWAY ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 172 NORWAY ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 173 NORWAY GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 174 NORWAY ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 175 NORWAY ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 176 NORWAY ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 177 NORWAY ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 178 HUNGARY ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 179 HUNGARY ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 180 HUNGARY BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 181 HUNGARY ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 182 HUNGARY ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 183 HUNGARY GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 184 HUNGARY ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 185 HUNGARY ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 186 HUNGARY ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 187 HUNGARY ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 188 LITHUANIA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 189 LITHUANIA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 190 LITHUANIA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 191 LITHUANIA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 192 LITHUANIA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 193 LITHUANIA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 194 LITHUANIA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 195 LITHUANIA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 196 LITHUANIA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 197 LITHUANIA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 198 IRELAND ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 199 IRELAND ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 200 IRELAND BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 201 IRELAND ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 202 IRELAND ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 203 IRELAND GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 204 IRELAND ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 205 IRELAND ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 206 IRELAND ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 207 IRELAND ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 208 POLAND ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 209 POLAND ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 210 POLAND BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 211 POLAND ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 212 POLAND ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 213 POLAND GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 214 POLAND ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 215 POLAND ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 216 POLAND ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 217 POLAND ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 218 REST OF EUROPE ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

FREQUENTLY ASK QUESTIONS

The Europe Adalimumab Market will be worth USD 10,337.79 million in the forecast period by 2029.
The Europe Adalimumab Market growth rate is 16.2% during the forecast period.
Increasing prevalence of rheumatoid arthritis, Rise in geriatric population and Increasing number of contract research organizations (CRO) are the growth drivers of the Europe Adalimumab Market.
Indication, type, dosage strength, drug type, population type, end user and distribution channel are the factors on which the Europe Adalimumab Market research is based.
Major companies in the Europe Adalimumab Market are AbbVie Inc. Sandoz International GmbH, Amgen Inc., Mylan N.V. (A subsidiary of Viatris), Biogen, Celltrion Healthcare Co., Ltd., Fresenius Kabi SwissBioSim GmbH, Alvotech, Biocad, Coherus BioSciences, Shanghai Henlius Biotech, Inc., Synermore Biologics, Prestige BioPharma Ltd., and Janssen Global Services etc.
Free Sample Report

CHOOSE LICENCE TYPE

  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials